[VIDEO PODCAST] Ep 10: QI for Advanced NSCLC

To support the optimization of care for patients with advanced non-small cell lung cancer (NSCLC), six ACCC Cancer Program Members applied to participate in a process improvement initiative.

Hear from Wendi Waugh, Director of Cancer Services, Southern Ohio Medical Center, as she walks us through the design and implementation of their plan, which focused on the need to better understand the causes of potentially preventable emergency department visits among patients with NSCLC who are undergoing active treatment. She'll then share her three tips for cancer programs who may consider a quality improvement approach to reviewing and improving their care processes.

Wendi Waugh, BS, RT(R)(T), CMD, CTR
Administrative Director of Cancer Services & Community Health and Wellness
Southern Ohio Medical Center

The ‘ah-ha’ moment was when we really got to looking at the results. We recognized that the provider who ordered the result, may or may not have even been informed that result was back and ready...so...we created a portal...[and] all these different results would automatically inform the provider and populate to the providers notes...It really improved the time from ordered, to receiving, to putting the treatment in action for the patient." — Wendi Waugh, BS, RT(R)(T), CMD, CTR

Related Resources

• Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC National NSCLC Quality Care Initiative
• NSCLC Resource Library
• 6 Steps to Improve Care Coordination for Lung Cancer Patients
• [PODCAST] Ep 24: Improving Lung Cancer Care
• Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer (NSCLC)
• Key Takeaways in Biomarker Testing, Patient Safety, Care Coordination, and Clinical Research for NSCLC
• Advanced NSCLC Biomarker Testing (CME/CMLE on-demand course)

To learn more about this education program, please visit the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC page. This project is made possible by support from AstraZeneca.